Edwards Lifesciences Corporation $EW Shares Sold by Patten & Patten Inc. TN

Patten & Patten Inc. TN trimmed its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 7.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 123,764 shares of the medical research company’s stock after selling 10,229 shares during the quarter. Patten & Patten Inc. TN’s holdings in Edwards Lifesciences were worth $9,625,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the stock. Rosenberg Matthew Hamilton purchased a new position in shares of Edwards Lifesciences in the 2nd quarter valued at about $28,000. True Wealth Design LLC raised its holdings in Edwards Lifesciences by 251.5% in the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 259 shares in the last quarter. NewSquare Capital LLC lifted its stake in Edwards Lifesciences by 57.8% in the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after acquiring an additional 134 shares during the last quarter. Rakuten Securities Inc. grew its holdings in Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after acquiring an additional 302 shares in the last quarter. Finally, Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at approximately $30,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW opened at $83.70 on Friday. The company’s 50 day simple moving average is $84.99 and its 200-day simple moving average is $80.83. The firm has a market cap of $48.57 billion, a PE ratio of 36.08, a price-to-earnings-growth ratio of 3.19 and a beta of 0.95. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The firm had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. Edwards Lifesciences’s quarterly revenue was up 14.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on EW. Wells Fargo & Company set a $100.00 price objective on shares of Edwards Lifesciences in a report on Thursday, December 18th. Robert W. Baird set a $90.00 price target on Edwards Lifesciences in a research note on Monday, January 12th. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $90.00 price target on shares of Edwards Lifesciences in a report on Monday, November 3rd. Stifel Nicolaus set a $110.00 price objective on Edwards Lifesciences and gave the stock a “buy” rating in a research report on Tuesday. Finally, Mizuho raised their target price on Edwards Lifesciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average target price of $96.82.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 11,386 shares of the business’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $83.76, for a total value of $953,691.36. Following the transaction, the vice president owned 38,970 shares in the company, valued at $3,264,127.20. The trade was a 22.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $83.08, for a total value of $1,080,040.00. Following the sale, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at approximately $3,314,725.84. This represents a 24.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 57,824 shares of company stock valued at $4,863,323 over the last quarter. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.